Study on Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE).
Phase of Trial: Phase IV
Latest Information Update: 16 May 2014
At a glance
- Drugs Cabergoline (Primary)
- Indications Hyperprolactinaemia; Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms SUCRE
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 28 Aug 2013 Interim results presented at the 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
- 03 Apr 2013 Planned end date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.